Travere Therapeutics Inc (NASDAQ: TVTX) on Friday, plunged -4.79% from the previous trading day, before settling in for the closing price of $19.00. Within the past 52 weeks, TVTX’s price has moved between $5.12 and $20.33.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 2.15% over the past five years. The company achieved an average annual earnings per share of -143.69%. With a float of $85.86 million, this company’s outstanding shares have now reached $87.03 million.
Let’s look at the performance matrix of the company that is accounted for 380 employees. In terms of profitability, gross margin is 84.29%, operating margin of -169.03%, and the pretax margin is -171.4%.
Travere Therapeutics Inc (TVTX) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Travere Therapeutics Inc is 1.49%, while institutional ownership is 97.35%. The most recent insider transaction that took place on Jan 03 ’25, was worth 39,461. In this transaction CHIEF MEDICAL OFFICER of this company sold 2,066 shares at a rate of $19.10, taking the stock ownership to the 59,883 shares. Before that another transaction happened on Jan 06 ’25, when Company’s CHIEF MEDICAL OFFICER sold 440 for $18.76, making the entire transaction worth $8,254. This insider now owns 59,443 shares in total.
Travere Therapeutics Inc (TVTX) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.31 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -143.69% per share during the next fiscal year.
Travere Therapeutics Inc (NASDAQ: TVTX) Trading Performance Indicators
Travere Therapeutics Inc (TVTX) is currently performing well based on its current performance indicators. A quick ratio of 1.68 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.74.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.56, a number that is poised to hit -0.58 in the next quarter and is forecasted to reach -1.14 in one year’s time.
Technical Analysis of Travere Therapeutics Inc (TVTX)
Travere Therapeutics Inc (NASDAQ: TVTX) saw its 5-day average volume 1.17 million, a negative change from its year-to-date volume of 1.2 million. As of the previous 9 days, the stock’s Stochastic %D was 73.33%. Additionally, its Average True Range was 0.83.
During the past 100 days, Travere Therapeutics Inc’s (TVTX) raw stochastic average was set at 81.13%, which indicates a significant increase from 54.38% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 48.67% in the past 14 days, which was lower than the 61.08% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $18.19, while its 200-day Moving Average is $11.79. Nevertheless, the first resistance level for the watch stands at $18.77 in the near term. At $19.45, the stock is likely to face the second major resistance level. The third major resistance level sits at $19.91. If the price goes on to break the first support level at $17.62, it is likely to go to the next support level at $17.16. Assuming the price breaks the second support level, the third support level stands at $16.48.
Travere Therapeutics Inc (NASDAQ: TVTX) Key Stats
Market capitalization of the company is 1.57 billion based on 78,050K outstanding shares. Right now, sales total 145,240 K and income totals -111,400 K. The company made 62,900 K in profit during its latest quarter, and -54,810 K in sales during its previous quarter.
